Development of an RBD-Fc fusion vaccine for COVID-19.

ABSTRACT: Although the global pandemic of SARS-CoV-2 has passed, there are still regional outbreaks that continue to jeopardize human health. Hence, there is still a great deal of interest in developing an efficient vaccine that can quickly and effectively prevent reemerging outbreaks of SARS-CoV-2. Delta variant was once a dominant strain in the world in 2021, and we first constructed a recombinant RBD_delta-Fc fusion vaccine by coupling the RBD of Delta variant with the human Fc fragment. This Fc fusion strategy increases the immunogenicity of the recombinant RBD vaccine, with a long-lasting high level of IgG antibodies and neutralizing antibodies induced by RBD_delta-Fc vaccine. This RBD_delta-Fc vaccine, as well as the RBD-Fc vaccine prepared in our previously study

SUBMITTER: Sun Y 

PROVIDER: S-EPMC10847155 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature